These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30762280)

  • 1. FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later.
    Bailey CJ
    Diabetes Obes Metab; 2019 May; 21(5):1079-1080. PubMed ID: 30762280
    [No Abstract]   [Full Text] [Related]  

  • 2. What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
    Covino J; Hoffman J
    JAAPA; 2018 Mar; 31(3):12-14. PubMed ID: 29470367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.
    Goyat R; Rai P; Chang J; Ponte CD; Tan X
    Clin Drug Investig; 2018 Jun; 38(6):491-501. PubMed ID: 29564723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of some antidiabetic drugs.
    Med Lett Drugs Ther; 2017 Aug; 59(1527):136-138. PubMed ID: 28787745
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of cardiovascular outcome trials in type 2 diabetes.
    Cypryk K; Małecki P
    Endokrynol Pol; 2018; 69(4):. PubMed ID: 30209802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of troglitazone.
    Umland EM; Romanelli AM
    Ann Pharmacother; 1999 Feb; 33(2):229-32. PubMed ID: 10084419
    [No Abstract]   [Full Text] [Related]  

  • 8. Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
    Campbell-Scherer D
    Evid Based Med; 2017 Apr; 22(2):57-58. PubMed ID: 28270434
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular Effects of Antidiabetic Therapies].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2017 May; 142(10):737-745. PubMed ID: 28514822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Wang D; Chen T; Yang X
    Circulation; 2019 Oct; 140(16):e720-e721. PubMed ID: 31609657
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
    Smith RJ; Goldfine AB; Hiatt WR
    Diabetes Care; 2016 May; 39(5):738-42. PubMed ID: 27208377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.
    Wikström G; Malmberg K; Rydén L
    Eur Heart J; 1999 Mar; 20(6):403-5. PubMed ID: 10213343
    [No Abstract]   [Full Text] [Related]  

  • 13. [Oral antidiabetic drugs. How to begin and combine without cardiovascular risk].
    Duarte R
    Rev Port Cardiol; 2013 Apr; 32 Suppl 1():15-24. PubMed ID: 23721975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-based benefit-risk assessment: can Archimedes help?
    Krishna R
    Clin Pharmacol Ther; 2009 Mar; 85(3):239-40. PubMed ID: 19223878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Lovre D; Htun W; Carrion C; Fonseca VA
    Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral antidiabetic therapy and cardiovascular complications: theoretical problem or clinical evidence?].
    Pogátsa G
    Orv Hetil; 2003 Apr; 144(14):645-50. PubMed ID: 12795025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.
    Lee G; Oh SW; Hwang SS; Yoon JW; Kang S; Joh HK; Kwon H; Kim J; Park D
    PLoS One; 2017; 12(5):e0177646. PubMed ID: 28542373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Antidiabetic Agents and Cardiovascular Outcomes.
    Pareek M; Bhatt DL
    Curr Probl Cardiol; 2018 Mar; 43(3):111-126. PubMed ID: 28844525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.